asked the U.S. District Court for Maryland to preemptively block the FDA from pulling the company's 2019 approval to distribute the company's version of mifepristone.
GenBioPro has said in court filings that it supplies two-thirds of the mifepristone used in the U.S. for abortions. The lawsuit was lodged in response to a ruling last week by the U.S. 5th Circuit Court of Appeal, which upheld part of a sweeping order by Texas U.S. District Judge Matthew Kacsmaryk that blocks GenBioPro's generic approval by the FDA.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: